Litton JK, Scoggins ME, Hess KR, et al. - Given talazoparib has shown efficacy in patients suffering from BRCA-positive metastatic breast cancer, researchers performed this study with patients having a known germline BRCA pathogenic variant (gBRCA-positive) and operable breast cancer, to assess the pathologic response of talazoparib alone for 6 months in these people. Cases with 1 cm or larger invasive tumor and gBRCA-positive disease were eligible for inclusion in the study. Those with human epidermal growth factor receptor 2–positive tumors were removed from the study. There were 20 patients in total who had a pretreatment biopsy and received 6 months of once per day oral talazoparib (1 mg), followed by definitive surgery. At physician’s discretion, adjuvant therapy was administered to the patients. Residual cancer burden (RCB) was assessed as the primary endpoint. A substantial RCB-0 rate with manageable toxicity was afforded by neoadjuvant single-agent oral talazoparib once per day for 6 months without chemotherapy. Findings also revealed substantive pathologic response to single-agent talazoparib.